Business
Mainz Biomed Appoints Former QIAGEN Executive Dr. Frank Krieg-Schneider as Vice President of Development
Dr. Frank Krieg-Schneider to lead development across Mainz Biomed’s portfolio of advanced cancer detection products including its flagship product ColoAlert
About this update from Quantum Cyber N.v.
[{"type":"text","content":"Dr. Frank Krieg-Schneider to lead development across Mainz Biomed’s portfolio of advanced cancer detection products including its flagship product ColoAlert and future diagnostic tests\nBERKELEY, Calif. and MAINZ, Germany, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Dr. Frank Krieg-Schneider as Vice President of Development. “Within the field of advanced diagnostics, it’s essential to have a strong and experienced team able to both innovate and to execute,” said Guido Baechler, Chief Executive Officer of Mainz Biomed. “We’re very excited to welcome Frank to our team who has honed his skills developing complex diagnostics tests for some of the largest and most successful organizations in the diagnostics industry. He will undoubtedly be a huge asset as we assess the potential to advance our ColoAlert product through the integration of our licensed portfolio of novel gene expression (mRNA) biomarkers and ensure compliance with stringent US regulatory standards to support our FDA submission.” Frank has over 25 years experience in the diagnostics and life science industry. He spent two decades in senior management and executive roles with global diagnostics leader, QIAGEN before being appointed to the role of CEO at molecular diagnostics firm GNA Biosolutions. He most recently led the clinical diagnostics division at one of Germany’s leading biotechnology companies, r-biopharm. In his tenure as a member of the QIAGEN Leadership Team, Frank led various divisions within the corporation’s diagnostic and life science practice, heading up R&D for Diagnostic Sample Preparation and later taking the role of Head of Global Strategic Alliances where grew OEM revenues from zero to high double-digit million USD, managing a global team of 50+ employees across multiple sites. As VP of Development at Mainz, Frank will lead development for the Company’s flagship product ColoAlert, its highly efficacious, and easy-to-use detection test for colorectal cancer (CRC). Mainz is currently marketing ColoAlert as a top-tier discretionary diagnostic option in Europe through its unique business model of partnering with third-party laboratories for test kit processing versus the tradit...